Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Cash from Operations: 2018-2024

Historic Cash from Operations for Revolution Medicines (RVMD) over the last 7 years, with Dec 2024 value amounting to -$557.4 million.

  • Revolution Medicines' Cash from Operations fell 58.96% to -$207.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$761.8 million, marking a year-over-year decrease of 41.15%. This contributed to the annual value of -$557.4 million for FY2024, which is 59.01% down from last year.
  • As of FY2024, Revolution Medicines' Cash from Operations stood at -$557.4 million, which was down 59.01% from -$350.6 million recorded in FY2023.
  • Over the past 5 years, Revolution Medicines' Cash from Operations peaked at -$100.1 million during FY2020, and registered a low of -$557.4 million during FY2024.
  • For the 3-year period, Revolution Medicines' Cash from Operations averaged around -$377.5 million, with its median value being -$350.6 million (2023).
  • Data for Revolution Medicines' Cash from Operations shows a maximum YoY slumped of 101.68% (in 2020) over the last 5 years.
  • Over the past 5 years, Revolution Medicines' Cash from Operations (Yearly) stood at -$100.1 million in 2020, then crashed by 47.09% to -$147.2 million in 2021, then slumped by 52.47% to -$224.4 million in 2022, then crashed by 56.23% to -$350.6 million in 2023, then plummeted by 59.01% to -$557.4 million in 2024.